Joshua Savage

8PUBLICATIONS
42CO-AUTHORS
Molecular targetsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 09, 2026
Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial.

|Dec 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.

Gary Middleton, Charlotte Gaskell, Joshua Savage

|Mar 12, 2025
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

Gary Middleton, Helen L Robbins, Peter Fletcher

|Nov 15, 2022
Protocol for the Tessa Jowell BRAIN MATRIX Platform Study.

Colin Watts, Joshua Savage, Amit Patel

|Mar 05, 2022
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.

Tobias Menne, Daniel Slade, Joshua Savage

|Nov 12, 2021
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults.

Tonny Veenith, Benjamin A Fisher, Daniel Slade

Pageof 2

Frequent Collaborators

3 joint publications

Lucinda Billingham

3 joint publications

Charles Swanton

3 joint publications

Manita Mehmi

2 joint publications

Pooja Jain